Sawai Pharmaceutical Co. Ltd., of Tokyo, and Upsher-Smith Laboratories Inc., of Minneapolis, signed a deal for Sawai to purchase the generic pharma business of Upsher-Smith from its parent, Acova Inc. Under the terms, Sawai will purchase all the equity interest in the generic pharma business for consideration of $1.05 billion. The deal is set to close near the end of June.